| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11224598 | OYSTER POINT PHARMA | Methods of increasing lacrimal proteins |
Oct, 2035
(12 years from now) | |
| US10456396 | OYSTER POINT PHARMA | Dry eye treatments |
Oct, 2035
(12 years from now) | |
| US9597284 | OYSTER POINT PHARMA | Dry eye treatments |
Oct, 2035
(12 years from now) | |
| US9532944 | OYSTER POINT PHARMA | Methods of improving ocular discomfort |
Oct, 2035
(12 years from now) | |
| US9504644 | OYSTER POINT PHARMA | Methods of increasing tear production |
Oct, 2035
(12 years from now) | |
| US9504645 | OYSTER POINT PHARMA | Pharmaceutical formulations for treating ocular conditions |
Oct, 2035
(12 years from now) | |
Tyrvaya is owned by Oyster Point Pharma.
Tyrvaya contains Varenicline Tartrate.
Tyrvaya has a total of 6 drug patents out of which 0 drug patents have expired.
Tyrvaya was authorised for market use on 15 October, 2021.
Tyrvaya is available in solution;nasal dosage forms.
Tyrvaya can be used as treatment of the signs and symptoms of dry eye disease (ded).
The generics of Tyrvaya are possible to be released after 19 October, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Oct 15, 2024 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION;NASAL
TYRVAYA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic